132 related articles for article (PubMed ID: 35441457)
21. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008].
Liao C; Shen DY; Xu XJ; Xu WQ; Zhang JY; Song H; Yang SL; Zhao FY; Shen HP; Tang YM
Zhonghua Er Ke Za Zhi; 2020 Sep; 58(9):758-763. PubMed ID: 32872717
[No Abstract] [Full Text] [Related]
22. Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
Brattås MK; Reikvam H; Tvedt THA; Bruserud Ø
Expert Opin Investig Drugs; 2019 May; 28(5):411-420. PubMed ID: 30916583
[TBL] [Abstract][Full Text] [Related]
23. [Outcome of children with T cell acute lymphoblastic leukemia treated with Chinese Children Leukemia Group acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol].
Liu XM; Chen XJ; Zou Y; Wang SC; Wang M; Zhang L; Chen YM; Yang WY; Guo Y; Zhu XF
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):761-766. PubMed ID: 31594062
[No Abstract] [Full Text] [Related]
24. [Dasatinib combined with multi-agent chemotherapy regimen in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective study from a single center].
Zhang GJ; Gong XY; Qiu SW; Zhou CL; Liu KQ; Lin D; Liu BC; Wei H; Wei SN; Li Y; Gu RX; Gong BF; Liu YT; Fang QY; Mi YC; Wang Y; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):109-115. PubMed ID: 33858040
[No Abstract] [Full Text] [Related]
25. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia.
Seki M; Kimura S; Isobe T; Yoshida K; Ueno H; Nakajima-Takagi Y; Wang C; Lin L; Kon A; Suzuki H; Shiozawa Y; Kataoka K; Fujii Y; Shiraishi Y; Chiba K; Tanaka H; Shimamura T; Masuda K; Kawamoto H; Ohki K; Kato M; Arakawa Y; Koh K; Hanada R; Moritake H; Akiyama M; Kobayashi R; Deguchi T; Hashii Y; Imamura T; Sato A; Kiyokawa N; Oka A; Hayashi Y; Takagi M; Manabe A; Ohara A; Horibe K; Sanada M; Iwama A; Mano H; Miyano S; Ogawa S; Takita J
Nat Genet; 2017 Aug; 49(8):1274-1281. PubMed ID: 28671687
[TBL] [Abstract][Full Text] [Related]
26. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
27. Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: a retrospective analysis.
Conter V; Valsecchi MG; Buldini B; Parasole R; Locatelli F; Colombini A; Rizzari C; Putti MC; Barisone E; Lo Nigro L; Santoro N; Ziino O; Pession A; Testi AM; Micalizzi C; Casale F; Pierani P; Cesaro S; Cellini M; Silvestri D; Cazzaniga G; Biondi A; Basso G
Lancet Haematol; 2016 Feb; 3(2):e80-6. PubMed ID: 26853647
[TBL] [Abstract][Full Text] [Related]
28. Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia.
Ma M; Wang X; Tang J; Xue H; Chen J; Pan C; Jiang H; Shen S
Front Med; 2012 Dec; 6(4):416-20. PubMed ID: 23065427
[TBL] [Abstract][Full Text] [Related]
29. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial.
Pan J; Tan Y; Wang G; Deng B; Ling Z; Song W; Seery S; Zhang Y; Peng S; Xu J; Duan J; Wang Z; Yu X; Zheng Q; Xu X; Yuan Y; Yan F; Tian Z; Tang K; Zhang J; Chang AH; Feng X
J Clin Oncol; 2021 Oct; 39(30):3340-3351. PubMed ID: 34324392
[TBL] [Abstract][Full Text] [Related]
30. Flow cytometric evaluation of CD38 expression levels in the newly diagnosed T-cell acute lymphoblastic leukemia and the effect of chemotherapy on its expression in measurable residual disease, refractory disease and relapsed disease: an implication for anti-CD38 immunotherapy.
Tembhare PR; Sriram H; Khanka T; Chatterjee G; Panda D; Ghogale S; Badrinath Y; Deshpande N; Patkar NV; Narula G; Bagal B; Jain H; Sengar M; Khattry N; Banavali S; Gujral S; Subramanian PG
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439800
[TBL] [Abstract][Full Text] [Related]
31. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
[TBL] [Abstract][Full Text] [Related]
32. Impact of T-cell immunity on chemotherapy response in childhood acute lymphoblastic leukemia.
Li Y; Yang X; Sun Y; Li Z; Yang W; Ju B; Easton J; Pei D; Cheng C; Lee S; Pui CH; Yu J; Chi H; Yang JJ
Blood; 2022 Sep; 140(13):1507-1521. PubMed ID: 35675514
[TBL] [Abstract][Full Text] [Related]
33. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
[TBL] [Abstract][Full Text] [Related]
34. The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy.
Yu S; Zhou X; Steinke FC; Liu C; Chen SC; Zagorodna O; Jing X; Yokota Y; Meyerholz DK; Mullighan CG; Knudson CM; Zhao DM; Xue HH
Immunity; 2012 Nov; 37(5):813-26. PubMed ID: 23103132
[TBL] [Abstract][Full Text] [Related]
35. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
[TBL] [Abstract][Full Text] [Related]
36. Two Elderly Patients with Philadelphia Chromosome Positive Mixed Phenotype Acute Leukemia Who Were Successfully Treated with Dasatinib and Prednisolone.
Takata H; Ikebe T; Sasaki H; Miyazaki Y; Ohtsuka E; Saburi Y; Ogata M; Shirao K
Intern Med; 2016; 55(9):1177-81. PubMed ID: 27150875
[TBL] [Abstract][Full Text] [Related]
37. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Foà R; Vitale A; Vignetti M; Meloni G; Guarini A; De Propris MS; Elia L; Paoloni F; Fazi P; Cimino G; Nobile F; Ferrara F; Castagnola C; Sica S; Leoni P; Zuffa E; Fozza C; Luppi M; Candoni A; Iacobucci I; Soverini S; Mandelli F; Martinelli G; Baccarani M;
Blood; 2011 Dec; 118(25):6521-8. PubMed ID: 21931113
[TBL] [Abstract][Full Text] [Related]
38. In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia.
Glover JM; Loriaux M; Tyner JW; Druker BJ; Chang BH
Pediatr Blood Cancer; 2012 Sep; 59(3):576-9. PubMed ID: 22038978
[TBL] [Abstract][Full Text] [Related]
39. Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies.
Cordo' V; Meijer MT; Hagelaar R; de Goeij-de Haas RR; Poort VM; Henneman AA; Piersma SR; Pham TV; Oshima K; Ferrando AA; Zaman GJR; Jimenez CR; Meijerink JPP
Nat Commun; 2022 Feb; 13(1):1048. PubMed ID: 35217681
[TBL] [Abstract][Full Text] [Related]
40. Dasatinib and chemotherapy in a patient with early T-cell precursor acute lymphoblastic leukemia and
Chen Y; Zhang L; Huang J; Hong X; Zhao J; Wang Z; Zhang K
Exp Ther Med; 2017 Nov; 14(5):3979-3984. PubMed ID: 29067094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
